

Lantern Pharma Announces Termination of Proposed Public Offering

Company Prioritizes Long-Term Shareholder Value Amid Unfavorable Near-Term Market Conditions; Remains Focused on Advancing High-Value Oncology Pipeline & AI Platform



Lantern Pharma®

Texas, United States Mar 30, 2026 ([Issuewire.com](https://www.Issuewire.com)) - Lantern Pharma Inc. (Nasdaq: LTRN) (the "Company"), a leading artificial intelligence ("AI") driven oncology company leveraging its proprietary RADR® platform to accelerate targeted cancer therapies, today announced the termination of its previously announced proposed public offering of shares of its common stock. As a result of such termination, no shares of the Company's common stock are being sold pursuant to the offering.

The decision to terminate the offering reflects management's assessment that current market conditions do not support a transaction on terms that would be in the long-term best interests of the Company and its shareholders. Lantern Pharma's management and Board of Directors remain firmly committed to pursuing capital formation strategies that appropriately reflect the intrinsic value of the Company's pipeline, AI platform, and development progress, and will continue to evaluate financing opportunities as market conditions evolve.

"We made a deliberate and disciplined decision to prioritize the long-term interests of our shareholders," said Panna Sharma, President and Chief Executive Officer of Lantern Pharma. "The current market environment does not adequately reflect the value of what we are building at Lantern, and we believe patience and strategic discipline serve our shareholders far better than executing a transaction under suboptimal conditions."

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company.

About Lantern Pharma

Lantern Pharma (Nasdaq: LTRN) is an AI company focused on transforming the cost, pace, and timeline of oncology drug discovery and development. The Company's proprietary AI and machine learning platform, RADR®, leverages approximately 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. For more information, visit www.lanternpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. The Company cautions readers not to place undue reliance on any forward-looking statements and does not undertake any obligation to update such statements except as required by law. Please refer to the Company's filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent reports, for a description of risks and uncertainties that could affect the Company's actual results.

Investor Relations Contact

Lantern Pharma Inc.

IR@lanternpharma.com

+1-972-277-1136

www.lanternpharma.com

Media Contact

Lantern Pharma Inc.

*****@LANTERNPHARMA.COM

+1-972-277-1136

1920 McKinney Avenue

Source : Lantern Pharma Inc.

[See on IssueWire](#)